Aerie Pharmaceuticals (AERI) Upgraded to Buy by BidaskClub

Aerie Pharmaceuticals (NASDAQ:AERI) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity set a $65.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 16th. JMP Securities set a $68.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $62.00 price target on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. Cowen reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. Finally, Mizuho reaffirmed a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $71.43.

Aerie Pharmaceuticals (AERI) opened at $61.40 on Tuesday. Aerie Pharmaceuticals has a one year low of $35.50 and a one year high of $66.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24.

Institutional investors have recently bought and sold shares of the business. AXA acquired a new position in Aerie Pharmaceuticals during the second quarter worth $10,961,000. Boulegeris Investments Inc. increased its position in Aerie Pharmaceuticals by 5.2% during the second quarter. Boulegeris Investments Inc. now owns 79,525 shares of the company’s stock worth $4,179,000 after buying an additional 3,900 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in shares of Aerie Pharmaceuticals by 8.5% in the second quarter. TIAA CREF Investment Management LLC now owns 124,238 shares of the company’s stock valued at $6,529,000 after purchasing an additional 9,781 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Aerie Pharmaceuticals by 64.8% in the second quarter. Bank of New York Mellon Corp now owns 436,955 shares of the company’s stock valued at $22,962,000 after purchasing an additional 171,879 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Aerie Pharmaceuticals by 1.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 138,289 shares of the company’s stock valued at $7,268,000 after purchasing an additional 2,183 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/05/aerie-pharmaceuticals-aeri-upgraded-to-buy-by-bidaskclub.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit